NEA Management Company, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), NEA Management Company, LLC reported 32 stock positions worth $1.3 billion. Its top holding was Arcellx (ACLX) at 18.6% of the portfolio, followed by Verona Pharma (VRNA, 16.1%) and Rhythm Pharmaceuticals (RYTM, 13.8%). Compared with Q1 2025, it opened 1 new position, sold out of 6, added to 4 and reduced 2. The biggest buy was Oric Pharmaceuticals (ORIC, shares +88%) and the biggest sale an exit from Tempus AI Class A (TEM).
- Most Recent 13F
- Q2 2026
- Location
- TIMONIUM, MD
- CIK
- 0001512848
- Portfolio Value
- $1.3B (Q2 2025)
- SEC Filing
- 0000897069-25-001334 ↗ filed Aug 14, 2025
Holdings Value
Holdings 32 stocks · $1.3B
| ACLX Arcellx Inc. | 18.56% | 3,745,262 | $246.6M | No change |
| VRNA Verona Pharma Ltd. | 16.11% | 2,263,138 | $214.0M | Reduce -15.8% |
| RYTM Rhythm Pharmaceuticals Inc. | 13.84% | 2,909,956 | $183.9M | No change |
| COUR Coursera Inc. | 8.49% | 12,867,769 | $112.7M | No change |
| CRSP Crispr Therapeutics AG | 5.81% | 1,587,854 | $77.2M | No change |
| TRVI Trevi Therapeutics Inc. | 5.44% | 13,222,228 | $72.3M | Add +16.3% |
| SVRA Savara Inc. | 4.20% | 24,471,264 | $55.8M | No change |
| ORIC Oric Pharmaceuticals Inc. | 3.15% | 4,118,621 | $41.8M | Add +87.6% |
| MBX MBX Biosciences Inc. | 3.10% | 3,614,486 | $41.2M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 2.61% | 7,692,298 | $34.7M | No change |
| AUPH Aurinia Pharmaceuticals Inc. | 2.53% | 3,969,834 | $33.6M | No change |
| CELC Celcuity Inc. | 2.31% | 2,294,261 | $30.6M | Add +83.5% |
| ZBIO Zenas Biopharma Inc. | 1.99% | 2,733,719 | $26.5M | Add +4.6% |
| GOSS Gossamer Bio Inc. | 1.68% | 18,093,034 | $22.3M | No change |
| NEUE Neuehealth Inc. | 1.42% | 2,726,917 | $18.8M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 1.42% | 1,960,169 | $18.8M | No change |
| KRRO Korro Bio Inc. | 1.03% | 1,090,793 | $13.6M | No change |
| CSBR Champions Oncology Inc. | 0.95% | 1,713,720 | $12.6M | No change |
| CVRX CVRX Inc. | 0.90% | 2,026,083 | $11.9M | No change |
| BDTX Black Diamond Therapeutics I | 0.83% | 4,448,757 | $11.0M | No change |
| INZY Inozyme Pharma Inc. | 0.73% | 2,437,689 | $9.8M | No change |
| SNTI Senti Biosciences Inc. | 0.60% | 3,775,615 | $8.0M | No change |
| OMDA Omada Health Inc. | 0.50% | 364,115 | $6.7M | New |
| NKTX Nkarta Inc. | 0.45% | 3,568,781 | $5.9M | No change |
| IVA Inventiva SA - ADR | 0.35% | 1,462,586 | $4.7M | No change |
| ADAPY Adaptimmune Therapeutics-ADR | 0.31% | 17,079,778 | $4.1M | No change |
| SYBX Synlogic Inc. | 0.28% | 2,922,772 | $3.7M | No change |
| MRKR Marker Therapeutics Inc. | 0.19% | 1,625,678 | $2.5M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.09% | 478,548 | $1.1M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.07% | 499,559 | $949K | Reduce -96.7% |
| IKENA ONCOLOGY INC | 0.06% | 600,063 | $804K | No change |
| UP Wheels Up Experience Inc. | 0.01% | 106,125 | $114K | No change |
Portfolio Sells Q1 2025 → Q2 2025
| TEM Tempus AI Inc. Class A | Sold out | 0.00% | −9.72 |
| RGLS Regulus Therapeutics Inc. | Sold out | 0.00% | −0.87 |
| DM Desktop Metal Inc. Class A | Sold out | 0.00% | −0.54 |
| BZFD Buzzfeed Inc. | Sold out | 0.00% | −0.41 |
| XFOR X4 Pharmaceuticals Inc. | Reduce -96.7% | 0.07% | −0.20 |
| ALLK Allakos LLC | Sold out | 0.00% | −0.11 |
| AFMDQ Affimed NV | Sold out | 0.00% | −0.02 |
| VRNA Verona Pharma Ltd. | Reduce -15.8% | 16.11% | +2.97 |
Portfolio Buys Q1 2025 → Q2 2025
Notes & Other Activity Q1 2025 → Q2 2025
| TUYA Tuya Inc. | SPONSERED ADS | Sold out | 0 | $0before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.6B | TRVI, MBX, GLUE, CELC, SGP |
| Q1 2026 | 26 | $1.8B | ACLX, CELC, SGP, TRVI, SVRA |
| Q4 2025 | 27 | $2.0B | CELC, RYTM, ACLX, TRVI, SVRA |
| Q3 2025 | 29 | $1.8B | RYTM, ACLX, VRNA, COUR, TRVI |
| Q2 2025 | 32 | $1.3B | ACLX, VRNA, RYTM, COUR, CRSP |
| Q1 2025 | 37 | $1.3B | ACLX, VRNA, RYTM, TEM, COUR |
| Q4 2024 | 41 | $1.8B | ACLX, VRNA, TEM, RYTM, NN |
| Q3 2024 | 42 | $1.8B | ACLX, TEM, VRNA, RYTM, SVRA |
| Q2 2024 | 41 | $1.3B | ACLX, TEM, RYTM, SVRA, COUR |
| Q1 2024 | 44 | $1.6B | ACLX, CRSP, RYTM, SVRA, COUR |